nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—SLCO1B3—Levothyroxine—hypothyroidism	0.107	0.131	CbGbCtD
Dabrafenib—SLCO1B3—Liothyronine—hypothyroidism	0.107	0.131	CbGbCtD
Dabrafenib—SLCO1B3—Liotrix—hypothyroidism	0.105	0.128	CbGbCtD
Dabrafenib—SLCO1B1—Dextrothyroxine—hypothyroidism	0.0823	0.101	CbGbCtD
Dabrafenib—SLCO1B1—Levothyroxine—hypothyroidism	0.0624	0.0764	CbGbCtD
Dabrafenib—SLCO1B1—Liothyronine—hypothyroidism	0.0624	0.0764	CbGbCtD
Dabrafenib—SLCO1B1—Liotrix—hypothyroidism	0.0609	0.0746	CbGbCtD
Dabrafenib—SLC22A8—Liothyronine—hypothyroidism	0.0576	0.0705	CbGbCtD
Dabrafenib—SLC22A8—Liotrix—hypothyroidism	0.0562	0.0688	CbGbCtD
Dabrafenib—CYP2C8—Levothyroxine—hypothyroidism	0.0264	0.0323	CbGbCtD
Dabrafenib—CYP2C8—Liotrix—hypothyroidism	0.0258	0.0316	CbGbCtD
Dabrafenib—ABCB1—Liothyronine—hypothyroidism	0.0179	0.0219	CbGbCtD
Dabrafenib—ABCB1—Levothyroxine—hypothyroidism	0.0179	0.0219	CbGbCtD
Dabrafenib—ABCB1—Liotrix—hypothyroidism	0.0174	0.0214	CbGbCtD
Dabrafenib—CYP3A4—Levothyroxine—hypothyroidism	0.0107	0.0131	CbGbCtD
Dabrafenib—NEK11—adrenal gland—hypothyroidism	0.00328	0.0398	CbGeAlD
Dabrafenib—Cardiac failure congestive—Liothyronine—hypothyroidism	0.00319	0.0551	CcSEcCtD
Dabrafenib—NEK11—thyroid gland—hypothyroidism	0.00317	0.0384	CbGeAlD
Dabrafenib—LIMK1—heart—hypothyroidism	0.00315	0.0381	CbGeAlD
Dabrafenib—NEK11—female gonad—hypothyroidism	0.00306	0.0371	CbGeAlD
Dabrafenib—SLC22A8—urine—hypothyroidism	0.00294	0.0356	CbGeAlD
Dabrafenib—NEK11—testis—hypothyroidism	0.00272	0.0329	CbGeAlD
Dabrafenib—NEK11—cerebellum—hypothyroidism	0.00251	0.0304	CbGeAlD
Dabrafenib—LIMK1—adrenal gland—hypothyroidism	0.00235	0.0285	CbGeAlD
Dabrafenib—LIMK1—blood—hypothyroidism	0.00235	0.0285	CbGeAlD
Dabrafenib—LIMK1—thyroid gland—hypothyroidism	0.00227	0.0275	CbGeAlD
Dabrafenib—BRAF—heart—hypothyroidism	0.00195	0.0236	CbGeAlD
Dabrafenib—LIMK1—testis—hypothyroidism	0.00194	0.0235	CbGeAlD
Dabrafenib—LIMK1—cerebellum—hypothyroidism	0.00179	0.0217	CbGeAlD
Dabrafenib—Arrhythmia—Liothyronine—hypothyroidism	0.00179	0.0309	CcSEcCtD
Dabrafenib—SIK1—heart—hypothyroidism	0.00163	0.0197	CbGeAlD
Dabrafenib—BRAF—pituitary gland—hypothyroidism	0.00163	0.0197	CbGeAlD
Dabrafenib—Cellulitis—Liotrix—hypothyroidism	0.00158	0.0273	CcSEcCtD
Dabrafenib—Hypocalcaemia—Liotrix—hypothyroidism	0.00157	0.0272	CcSEcCtD
Dabrafenib—Cardiac failure congestive—Dextrothyroxine—hypothyroidism	0.00157	0.0271	CcSEcCtD
Dabrafenib—Cardiac failure congestive—Levothyroxine—hypothyroidism	0.00157	0.0271	CcSEcCtD
Dabrafenib—Creatinine increased—Liotrix—hypothyroidism	0.00151	0.0261	CcSEcCtD
Dabrafenib—Hypertension—Liothyronine—hypothyroidism	0.0015	0.026	CcSEcCtD
Dabrafenib—CYP3A4—urine—hypothyroidism	0.00146	0.0177	CbGeAlD
Dabrafenib—BRAF—adrenal gland—hypothyroidism	0.00145	0.0176	CbGeAlD
Dabrafenib—BRAF—blood—hypothyroidism	0.00145	0.0176	CbGeAlD
Dabrafenib—RAF1—Nongenotropic Androgen signaling—SHBG—hypothyroidism	0.00142	0.0334	CbGpPWpGaD
Dabrafenib—BRAF—thyroid gland—hypothyroidism	0.0014	0.017	CbGeAlD
Dabrafenib—SLCO1B3—pituitary gland—hypothyroidism	0.0014	0.017	CbGeAlD
Dabrafenib—SIK1—gonad—hypothyroidism	0.00139	0.0169	CbGeAlD
Dabrafenib—SLCO1B3—Transport of organic anions—AVP—hypothyroidism	0.00138	0.0324	CbGpPWpGaD
Dabrafenib—SIK1—pituitary gland—hypothyroidism	0.00136	0.0165	CbGeAlD
Dabrafenib—BRAF—female gonad—hypothyroidism	0.00135	0.0164	CbGeAlD
Dabrafenib—BRAF—CREB phosphorylation through the activation of Ras—NEFL—hypothyroidism	0.00134	0.0315	CbGpPWpGaD
Dabrafenib—RAF1—adrenal cortex—hypothyroidism	0.00134	0.0162	CbGeAlD
Dabrafenib—Hypotension—Liothyronine—hypothyroidism	0.00133	0.0229	CcSEcCtD
Dabrafenib—BRAF—TSH signaling pathway—PAX8—hypothyroidism	0.00132	0.0311	CbGpPWpGaD
Dabrafenib—Dehydration—Dextrothyroxine—hypothyroidism	0.00132	0.0228	CcSEcCtD
Dabrafenib—Dehydration—Levothyroxine—hypothyroidism	0.00132	0.0228	CcSEcCtD
Dabrafenib—SIK1—Circadian rythm related genes—NKX2-1—hypothyroidism	0.0013	0.0306	CbGpPWpGaD
Dabrafenib—RAF1—heart—hypothyroidism	0.0013	0.0157	CbGeAlD
Dabrafenib—RAF1—cardiovascular system—hypothyroidism	0.00122	0.0148	CbGeAlD
Dabrafenib—SIK1—adrenal gland—hypothyroidism	0.00122	0.0147	CbGeAlD
Dabrafenib—SIK1—blood—hypothyroidism	0.00122	0.0147	CbGeAlD
Dabrafenib—BRAF—testis—hypothyroidism	0.0012	0.0145	CbGeAlD
Dabrafenib—SIK1—thyroid gland—hypothyroidism	0.00117	0.0142	CbGeAlD
Dabrafenib—Cardiac failure congestive—Liotrix—hypothyroidism	0.00115	0.0199	CcSEcCtD
Dabrafenib—BRAF—liver—hypothyroidism	0.00114	0.0137	CbGeAlD
Dabrafenib—SIK1—female gonad—hypothyroidism	0.00113	0.0137	CbGeAlD
Dabrafenib—Renal failure acute—Liotrix—hypothyroidism	0.00113	0.0196	CcSEcCtD
Dabrafenib—LIMK1—EPH-Ephrin signaling—CLTC—hypothyroidism	0.00113	0.0265	CbGpPWpGaD
Dabrafenib—Body temperature increased—Liothyronine—hypothyroidism	0.00112	0.0194	CcSEcCtD
Dabrafenib—RAF1—gonad—hypothyroidism	0.00111	0.0134	CbGeAlD
Dabrafenib—BRAF—cerebellum—hypothyroidism	0.00111	0.0134	CbGeAlD
Dabrafenib—BRAF—Post NMDA receptor activation events—NEFL—hypothyroidism	0.0011	0.0259	CbGpPWpGaD
Dabrafenib—RAF1—pituitary gland—hypothyroidism	0.00108	0.0131	CbGeAlD
Dabrafenib—BRAF—Activation of NMDA receptor upon glutamate binding and postsynaptic events—NEFL—hypothyroidism	0.00102	0.0239	CbGpPWpGaD
Dabrafenib—SIK1—testis—hypothyroidism	0.00101	0.0122	CbGeAlD
Dabrafenib—Blood creatinine increased—Liotrix—hypothyroidism	0.000979	0.0169	CcSEcCtD
Dabrafenib—SLCO1B3—liver—hypothyroidism	0.000978	0.0118	CbGeAlD
Dabrafenib—Dehydration—Liotrix—hypothyroidism	0.000972	0.0168	CcSEcCtD
Dabrafenib—RAF1—adrenal gland—hypothyroidism	0.000967	0.0117	CbGeAlD
Dabrafenib—RAF1—blood—hypothyroidism	0.000967	0.0117	CbGeAlD
Dabrafenib—Hypokalaemia—Liotrix—hypothyroidism	0.000951	0.0164	CcSEcCtD
Dabrafenib—SIK1—liver—hypothyroidism	0.00095	0.0115	CbGeAlD
Dabrafenib—RAF1—thyroid gland—hypothyroidism	0.000933	0.0113	CbGeAlD
Dabrafenib—RAF1—CREB phosphorylation through the activation of Ras—NEFL—hypothyroidism	0.000928	0.0218	CbGpPWpGaD
Dabrafenib—SIK1—cerebellum—hypothyroidism	0.000928	0.0112	CbGeAlD
Dabrafenib—SLCO1B1—Transport of organic anions—AVP—hypothyroidism	0.000927	0.0218	CbGpPWpGaD
Dabrafenib—RAF1—TSH signaling pathway—PAX8—hypothyroidism	0.000915	0.0215	CbGpPWpGaD
Dabrafenib—RAF1—female gonad—hypothyroidism	0.000902	0.0109	CbGeAlD
Dabrafenib—Arrhythmia—Levothyroxine—hypothyroidism	0.000878	0.0152	CcSEcCtD
Dabrafenib—Arrhythmia—Dextrothyroxine—hypothyroidism	0.000878	0.0152	CcSEcCtD
Dabrafenib—Alopecia—Dextrothyroxine—hypothyroidism	0.000868	0.015	CcSEcCtD
Dabrafenib—Alopecia—Levothyroxine—hypothyroidism	0.000868	0.015	CcSEcCtD
Dabrafenib—RAF1—testis—hypothyroidism	0.0008	0.00969	CbGeAlD
Dabrafenib—LIMK1—Regulation of actin dynamics for phagocytic cup formation—VAV3—hypothyroidism	0.000792	0.0186	CbGpPWpGaD
Dabrafenib—Renal failure—Liotrix—hypothyroidism	0.000792	0.0137	CcSEcCtD
Dabrafenib—RAF1—Post NMDA receptor activation events—NEFL—hypothyroidism	0.000764	0.0179	CbGpPWpGaD
Dabrafenib—RAF1—liver—hypothyroidism	0.000756	0.00916	CbGeAlD
Dabrafenib—RAF1—cerebellum—hypothyroidism	0.000739	0.00895	CbGeAlD
Dabrafenib—Arthralgia—Dextrothyroxine—hypothyroidism	0.000728	0.0126	CcSEcCtD
Dabrafenib—Arthralgia—Levothyroxine—hypothyroidism	0.000728	0.0126	CcSEcCtD
Dabrafenib—SLCO1B1—blood—hypothyroidism	0.000724	0.00876	CbGeAlD
Dabrafenib—RAF1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—NEFL—hypothyroidism	0.000704	0.0165	CbGpPWpGaD
Dabrafenib—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A7—hypothyroidism	0.00068	0.016	CbGpPWpGaD
Dabrafenib—Hyperhidrosis—Dextrothyroxine—hypothyroidism	0.000675	0.0117	CcSEcCtD
Dabrafenib—Hyperhidrosis—Levothyroxine—hypothyroidism	0.000675	0.0117	CcSEcCtD
Dabrafenib—Arrhythmia—Liotrix—hypothyroidism	0.000646	0.0112	CcSEcCtD
Dabrafenib—Alopecia—Liotrix—hypothyroidism	0.000639	0.011	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Dextrothyroxine—hypothyroidism	0.000636	0.011	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Levothyroxine—hypothyroidism	0.000636	0.011	CcSEcCtD
Dabrafenib—Insomnia—Dextrothyroxine—hypothyroidism	0.000632	0.0109	CcSEcCtD
Dabrafenib—Insomnia—Levothyroxine—hypothyroidism	0.000632	0.0109	CcSEcCtD
Dabrafenib—Fatigue—Levothyroxine—hypothyroidism	0.000602	0.0104	CcSEcCtD
Dabrafenib—Fatigue—Dextrothyroxine—hypothyroidism	0.000602	0.0104	CcSEcCtD
Dabrafenib—LIMK1—Fcgamma receptor (FCGR) dependent phagocytosis—VAV3—hypothyroidism	0.000598	0.014	CbGpPWpGaD
Dabrafenib—Vision blurred—Liotrix—hypothyroidism	0.000593	0.0102	CcSEcCtD
Dabrafenib—BRAF—TSH signaling pathway—TSHR—hypothyroidism	0.000576	0.0135	CbGpPWpGaD
Dabrafenib—BRAF—TSH signaling pathway—TSHB—hypothyroidism	0.000576	0.0135	CbGpPWpGaD
Dabrafenib—Gastrointestinal pain—Levothyroxine—hypothyroidism	0.000571	0.00986	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Dextrothyroxine—hypothyroidism	0.000571	0.00986	CcSEcCtD
Dabrafenib—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A7—hypothyroidism	0.000568	0.0133	CbGpPWpGaD
Dabrafenib—SLCO1B1—liver—hypothyroidism	0.000566	0.00685	CbGeAlD
Dabrafenib—SLC22A8—blood—hypothyroidism	0.000562	0.00681	CbGeAlD
Dabrafenib—ABCG2—adrenal cortex—hypothyroidism	0.000554	0.00671	CbGeAlD
Dabrafenib—Abdominal pain—Levothyroxine—hypothyroidism	0.000552	0.00953	CcSEcCtD
Dabrafenib—Abdominal pain—Dextrothyroxine—hypothyroidism	0.000552	0.00953	CcSEcCtD
Dabrafenib—Body temperature increased—Dextrothyroxine—hypothyroidism	0.000552	0.00953	CcSEcCtD
Dabrafenib—Body temperature increased—Levothyroxine—hypothyroidism	0.000552	0.00953	CcSEcCtD
Dabrafenib—Hypertension—Liotrix—hypothyroidism	0.000543	0.00939	CcSEcCtD
Dabrafenib—ABCG2—heart—hypothyroidism	0.000536	0.00649	CbGeAlD
Dabrafenib—Arthralgia—Liotrix—hypothyroidism	0.000536	0.00925	CcSEcCtD
Dabrafenib—LIMK1—Regulation of Actin Cytoskeleton—PIK3C2A—hypothyroidism	0.000535	0.0126	CbGpPWpGaD
Dabrafenib—LIMK1—EPH-Ephrin signaling—VAV3—hypothyroidism	0.000531	0.0125	CbGpPWpGaD
Dabrafenib—Oedema—Liotrix—hypothyroidism	0.000514	0.00887	CcSEcCtD
Dabrafenib—SLCO1B3—Transport of vitamins, nucleosides, and related molecules—AVP—hypothyroidism	0.000512	0.012	CbGpPWpGaD
Dabrafenib—Infection—Liotrix—hypothyroidism	0.00051	0.00881	CcSEcCtD
Dabrafenib—Asthenia—Dextrothyroxine—hypothyroidism	0.000501	0.00865	CcSEcCtD
Dabrafenib—Asthenia—Levothyroxine—hypothyroidism	0.000501	0.00865	CcSEcCtD
Dabrafenib—Hyperhidrosis—Liotrix—hypothyroidism	0.000496	0.00858	CcSEcCtD
Dabrafenib—SIK1—Circadian rythm related genes—AVP—hypothyroidism	0.000495	0.0116	CbGpPWpGaD
Dabrafenib—RAF1—Interleukin-11 Signaling Pathway—BGLAP—hypothyroidism	0.000494	0.0116	CbGpPWpGaD
Dabrafenib—Pruritus—Dextrothyroxine—hypothyroidism	0.000494	0.00853	CcSEcCtD
Dabrafenib—Pruritus—Levothyroxine—hypothyroidism	0.000494	0.00853	CcSEcCtD
Dabrafenib—Hypotension—Liotrix—hypothyroidism	0.00048	0.00829	CcSEcCtD
Dabrafenib—Diarrhoea—Dextrothyroxine—hypothyroidism	0.000478	0.00825	CcSEcCtD
Dabrafenib—Diarrhoea—Levothyroxine—hypothyroidism	0.000478	0.00825	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Liotrix—hypothyroidism	0.000468	0.00808	CcSEcCtD
Dabrafenib—Insomnia—Liotrix—hypothyroidism	0.000465	0.00802	CcSEcCtD
Dabrafenib—CYP2C8—pituitary gland—hypothyroidism	0.000461	0.00558	CbGeAlD
Dabrafenib—ABCG2—pituitary gland—hypothyroidism	0.000448	0.00542	CbGeAlD
Dabrafenib—Decreased appetite—Liotrix—hypothyroidism	0.000446	0.00771	CcSEcCtD
Dabrafenib—BRAF—Transmission across Chemical Synapses—SLC5A7—hypothyroidism	0.000444	0.0104	CbGpPWpGaD
Dabrafenib—Vomiting—Dextrothyroxine—hypothyroidism	0.000444	0.00767	CcSEcCtD
Dabrafenib—Vomiting—Levothyroxine—hypothyroidism	0.000444	0.00767	CcSEcCtD
Dabrafenib—Fatigue—Liotrix—hypothyroidism	0.000443	0.00765	CcSEcCtD
Dabrafenib—Rash—Dextrothyroxine—hypothyroidism	0.00044	0.0076	CcSEcCtD
Dabrafenib—Rash—Levothyroxine—hypothyroidism	0.00044	0.0076	CcSEcCtD
Dabrafenib—Dermatitis—Levothyroxine—hypothyroidism	0.00044	0.0076	CcSEcCtD
Dabrafenib—Dermatitis—Dextrothyroxine—hypothyroidism	0.00044	0.0076	CcSEcCtD
Dabrafenib—Constipation—Liotrix—hypothyroidism	0.000439	0.00759	CcSEcCtD
Dabrafenib—Headache—Dextrothyroxine—hypothyroidism	0.000437	0.00756	CcSEcCtD
Dabrafenib—Headache—Levothyroxine—hypothyroidism	0.000437	0.00756	CcSEcCtD
Dabrafenib—RAF1—Signaling events mediated by Stem cell factor receptor (c-Kit)—SH2B3—hypothyroidism	0.000436	0.0102	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways in Glioblastoma—PIK3C2A—hypothyroidism	0.000431	0.0101	CbGpPWpGaD
Dabrafenib—Gastrointestinal pain—Liotrix—hypothyroidism	0.00042	0.00725	CcSEcCtD
Dabrafenib—LIMK1—Axon guidance—CLTC—hypothyroidism	0.000419	0.00983	CbGpPWpGaD
Dabrafenib—Nausea—Levothyroxine—hypothyroidism	0.000415	0.00716	CcSEcCtD
Dabrafenib—Nausea—Dextrothyroxine—hypothyroidism	0.000415	0.00716	CcSEcCtD
Dabrafenib—CYP2C8—blood—hypothyroidism	0.000411	0.00498	CbGeAlD
Dabrafenib—Abdominal pain—Liotrix—hypothyroidism	0.000406	0.00701	CcSEcCtD
Dabrafenib—Body temperature increased—Liotrix—hypothyroidism	0.000406	0.00701	CcSEcCtD
Dabrafenib—ABCG2—adrenal gland—hypothyroidism	0.0004	0.00485	CbGeAlD
Dabrafenib—ABCG2—blood—hypothyroidism	0.0004	0.00485	CbGeAlD
Dabrafenib—RAF1—TSH signaling pathway—TSHB—hypothyroidism	0.000398	0.00935	CbGpPWpGaD
Dabrafenib—RAF1—TSH signaling pathway—TSHR—hypothyroidism	0.000398	0.00935	CbGpPWpGaD
Dabrafenib—ABCG2—thyroid gland—hypothyroidism	0.000386	0.00468	CbGeAlD
Dabrafenib—BRAF—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—NEFL—hypothyroidism	0.000381	0.00894	CbGpPWpGaD
Dabrafenib—Hypersensitivity—Liotrix—hypothyroidism	0.000378	0.00654	CcSEcCtD
Dabrafenib—ABCG2—female gonad—hypothyroidism	0.000373	0.00452	CbGeAlD
Dabrafenib—Asthenia—Liotrix—hypothyroidism	0.000368	0.00637	CcSEcCtD
Dabrafenib—Pruritus—Liotrix—hypothyroidism	0.000363	0.00628	CcSEcCtD
Dabrafenib—RAF1—Regulation of retinoblastoma protein—BGLAP—hypothyroidism	0.000357	0.00839	CbGpPWpGaD
Dabrafenib—Diarrhoea—Liotrix—hypothyroidism	0.000351	0.00607	CcSEcCtD
Dabrafenib—SLCO1B3—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.000349	0.0082	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transport of vitamins, nucleosides, and related molecules—AVP—hypothyroidism	0.000344	0.00808	CbGpPWpGaD
Dabrafenib—RAF1—FCERI mediated MAPK activation—VAV3—hypothyroidism	0.000343	0.00806	CbGpPWpGaD
Dabrafenib—BRAF—Neuronal System—SLC5A7—hypothyroidism	0.00034	0.00799	CbGpPWpGaD
Dabrafenib—CYP2C8—testis—hypothyroidism	0.00034	0.00412	CbGeAlD
Dabrafenib—Dizziness—Liotrix—hypothyroidism	0.00034	0.00587	CcSEcCtD
Dabrafenib—ABCG2—testis—hypothyroidism	0.000331	0.00401	CbGeAlD
Dabrafenib—Vomiting—Liotrix—hypothyroidism	0.000327	0.00564	CcSEcCtD
Dabrafenib—RAF1—SHC-related events triggered by IGF1R—IGF1—hypothyroidism	0.000326	0.00766	CbGpPWpGaD
Dabrafenib—Rash—Liotrix—hypothyroidism	0.000324	0.00559	CcSEcCtD
Dabrafenib—Dermatitis—Liotrix—hypothyroidism	0.000324	0.00559	CcSEcCtD
Dabrafenib—Headache—Liotrix—hypothyroidism	0.000322	0.00556	CcSEcCtD
Dabrafenib—CYP2C8—liver—hypothyroidism	0.000322	0.0039	CbGeAlD
Dabrafenib—ABCG2—liver—hypothyroidism	0.000313	0.00379	CbGeAlD
Dabrafenib—SLC22A8—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.000309	0.00726	CbGpPWpGaD
Dabrafenib—RAF1—Transmission across Chemical Synapses—SLC5A7—hypothyroidism	0.000307	0.00722	CbGpPWpGaD
Dabrafenib—ABCG2—cerebellum—hypothyroidism	0.000306	0.0037	CbGeAlD
Dabrafenib—Nausea—Liotrix—hypothyroidism	0.000305	0.00527	CcSEcCtD
Dabrafenib—LIMK1—Developmental Biology—CLTC—hypothyroidism	0.000299	0.00702	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways in Glioblastoma—PIK3C2A—hypothyroidism	0.000298	0.00701	CbGpPWpGaD
Dabrafenib—SLCO1B3—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.000289	0.0068	CbGpPWpGaD
Dabrafenib—BRAF—Transmission across Chemical Synapses—NEFL—hypothyroidism	0.000286	0.00672	CbGpPWpGaD
Dabrafenib—RAF1—IGF1 pathway—IGF1—hypothyroidism	0.000282	0.00662	CbGpPWpGaD
Dabrafenib—CYP3A4—blood—hypothyroidism	0.000279	0.00338	CbGeAlD
Dabrafenib—RAF1—TCR Signaling Pathway—SH2B3—hypothyroidism	0.000277	0.00651	CbGpPWpGaD
Dabrafenib—ABCB1—adrenal cortex—hypothyroidism	0.000273	0.00331	CbGeAlD
Dabrafenib—BRAF—Regulation of Actin Cytoskeleton—PIK3C2A—hypothyroidism	0.000268	0.00628	CbGpPWpGaD
Dabrafenib—ABCB1—heart—hypothyroidism	0.000264	0.0032	CbGeAlD
Dabrafenib—RAF1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—NEFL—hypothyroidism	0.000263	0.00619	CbGpPWpGaD
Dabrafenib—SLC22A6—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.000258	0.00606	CbGpPWpGaD
Dabrafenib—SLC22A8—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.000256	0.00601	CbGpPWpGaD
Dabrafenib—BRAF—Integrin-mediated Cell Adhesion—VAV3—hypothyroidism	0.000253	0.00593	CbGpPWpGaD
Dabrafenib—ABCB1—cardiovascular system—hypothyroidism	0.000249	0.00302	CbGeAlD
Dabrafenib—RAF1—Neuronal System—SLC5A7—hypothyroidism	0.000235	0.00553	CbGpPWpGaD
Dabrafenib—SLCO1B1—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.000235	0.00551	CbGpPWpGaD
Dabrafenib—ABCB1—gonad—hypothyroidism	0.000226	0.00274	CbGeAlD
Dabrafenib—ABCB1—pituitary gland—hypothyroidism	0.000221	0.00267	CbGeAlD
Dabrafenib—BRAF—Neuronal System—NEFL—hypothyroidism	0.000219	0.00515	CbGpPWpGaD
Dabrafenib—CYP3A4—liver—hypothyroidism	0.000218	0.00264	CbGeAlD
Dabrafenib—SLC22A6—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.000214	0.00502	CbGpPWpGaD
Dabrafenib—RAF1—Transmission across Chemical Synapses—NEFL—hypothyroidism	0.000198	0.00465	CbGpPWpGaD
Dabrafenib—ABCB1—adrenal gland—hypothyroidism	0.000197	0.00239	CbGeAlD
Dabrafenib—LIMK1—Axon guidance—VAV3—hypothyroidism	0.000197	0.00463	CbGpPWpGaD
Dabrafenib—ABCB1—blood—hypothyroidism	0.000197	0.00239	CbGeAlD
Dabrafenib—SLCO1B1—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.000194	0.00457	CbGpPWpGaD
Dabrafenib—RAF1—Ceramide signaling pathway—IGF1—hypothyroidism	0.000194	0.00455	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—SH2B3—hypothyroidism	0.000193	0.00454	CbGpPWpGaD
Dabrafenib—ABCB1—thyroid gland—hypothyroidism	0.00019	0.00231	CbGeAlD
Dabrafenib—RAF1—TCR Signaling Pathway—VAV3—hypothyroidism	0.00019	0.00447	CbGpPWpGaD
Dabrafenib—RAF1—Regulation of Actin Cytoskeleton—PIK3C2A—hypothyroidism	0.000185	0.00435	CbGpPWpGaD
Dabrafenib—ABCB1—female gonad—hypothyroidism	0.000184	0.00223	CbGeAlD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000178	0.00417	CbGpPWpGaD
Dabrafenib—RAF1—Insulin Signaling—PIK3C2A—hypothyroidism	0.000175	0.00411	CbGpPWpGaD
Dabrafenib—RAF1—Integrin-mediated Cell Adhesion—VAV3—hypothyroidism	0.000175	0.0041	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—TRH—hypothyroidism	0.000174	0.00408	CbGpPWpGaD
Dabrafenib—RAF1—Cardiac Hypertrophic Response—IGF1—hypothyroidism	0.000174	0.00408	CbGpPWpGaD
Dabrafenib—BRAF—Corticotropin-releasing hormone—POMC—hypothyroidism	0.000173	0.00406	CbGpPWpGaD
Dabrafenib—BRAF—EGF/EGFR Signaling Pathway—VAV3—hypothyroidism	0.000172	0.00403	CbGpPWpGaD
Dabrafenib—RAF1—SHP2 signaling—IGF1—hypothyroidism	0.000166	0.00391	CbGpPWpGaD
Dabrafenib—RAF1—VEGFA-VEGFR2 Pathway—VAV3—hypothyroidism	0.000166	0.00389	CbGpPWpGaD
Dabrafenib—ABCB1—testis—hypothyroidism	0.000163	0.00198	CbGeAlD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000157	0.00369	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by VEGF—VAV3—hypothyroidism	0.000156	0.00367	CbGpPWpGaD
Dabrafenib—ABCB1—liver—hypothyroidism	0.000154	0.00187	CbGeAlD
Dabrafenib—LIMK1—Immune System—CLTC—hypothyroidism	0.000154	0.00361	CbGpPWpGaD
Dabrafenib—RAF1—Neuronal System—NEFL—hypothyroidism	0.000152	0.00356	CbGpPWpGaD
Dabrafenib—ABCB1—cerebellum—hypothyroidism	0.000151	0.00183	CbGeAlD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—IGF1—hypothyroidism	0.00015	0.00351	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000147	0.00345	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—CLTC—hypothyroidism	0.000145	0.0034	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—VAV3—hypothyroidism	0.000141	0.00331	CbGpPWpGaD
Dabrafenib—SLCO1B3—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.00014	0.00328	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—PRL—hypothyroidism	0.000135	0.00317	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000131	0.00308	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—VAV3—hypothyroidism	0.000131	0.00307	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.00013	0.00306	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000127	0.00297	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—VAV3—hypothyroidism	0.000124	0.00292	CbGpPWpGaD
Dabrafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—IGF1—hypothyroidism	0.000124	0.00291	CbGpPWpGaD
Dabrafenib—SLC22A8—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000124	0.0029	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—IYD—hypothyroidism	0.00012	0.00282	CbGpPWpGaD
Dabrafenib—RAF1—Corticotropin-releasing hormone—POMC—hypothyroidism	0.00012	0.00281	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000119	0.0028	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—VAV3—hypothyroidism	0.000119	0.00279	CbGpPWpGaD
Dabrafenib—RAF1—IRS-related events triggered by IGF1R—IGF1—hypothyroidism	0.000118	0.00277	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—VAV3—hypothyroidism	0.000118	0.00276	CbGpPWpGaD
Dabrafenib—RAF1—IGF1R signaling cascade—IGF1—hypothyroidism	0.000115	0.0027	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—VAV3—hypothyroidism	0.000111	0.0026	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—VAV3—hypothyroidism	0.000111	0.0026	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.00011	0.00259	CbGpPWpGaD
Dabrafenib—SLCO1B3—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.00011	0.00258	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—VAV3—hypothyroidism	0.000109	0.00256	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000109	0.00255	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000105	0.00246	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—IGF1—hypothyroidism	0.000104	0.00243	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—CLTC—hypothyroidism	0.000103	0.00243	CbGpPWpGaD
Dabrafenib—SLC22A6—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000103	0.00242	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ATP5O—hypothyroidism	0.000102	0.00239	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	9.88e-05	0.00232	CbGpPWpGaD
Dabrafenib—SLC22A8—SLC-mediated transmembrane transport—AVP—hypothyroidism	9.73e-05	0.00228	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—TPO—hypothyroidism	9.59e-05	0.00225	CbGpPWpGaD
Dabrafenib—SLCO1B1—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	9.38e-05	0.0022	CbGpPWpGaD
Dabrafenib—BRAF—Focal Adhesion—IGF1—hypothyroidism	9.31e-05	0.00219	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—VAV3—hypothyroidism	9.27e-05	0.00218	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	9.15e-05	0.00215	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—hypothyroidism	9.13e-05	0.00214	CbGpPWpGaD
Dabrafenib—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	9.11e-05	0.00214	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	8.88e-05	0.00209	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CLTC—hypothyroidism	8.76e-05	0.00206	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—PRL—hypothyroidism	8.29e-05	0.00195	CbGpPWpGaD
Dabrafenib—SLC22A6—SLC-mediated transmembrane transport—AVP—hypothyroidism	8.12e-05	0.00191	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—IYD—hypothyroidism	8.06e-05	0.00189	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—PRL—hypothyroidism	7.83e-05	0.00184	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—VAV3—hypothyroidism	7.54e-05	0.00177	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—IYD—hypothyroidism	7.46e-05	0.00175	CbGpPWpGaD
Dabrafenib—CYP2C8—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	7.39e-05	0.00174	CbGpPWpGaD
Dabrafenib—SLCO1B1—SLC-mediated transmembrane transport—AVP—hypothyroidism	7.39e-05	0.00173	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—VAV3—hypothyroidism	7.24e-05	0.0017	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	7.09e-05	0.00167	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—SH2B3—hypothyroidism	6.96e-05	0.00163	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ATP5O—hypothyroidism	6.85e-05	0.00161	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—VAV3—hypothyroidism	6.82e-05	0.0016	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—TPO—hypothyroidism	6.44e-05	0.00151	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—IGF1—hypothyroidism	6.44e-05	0.00151	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	6.41e-05	0.00151	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ATP5O—hypothyroidism	6.34e-05	0.00149	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	6.28e-05	0.00147	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	5.97e-05	0.0014	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	5.97e-05	0.0014	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—TPO—hypothyroidism	5.97e-05	0.0014	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—IGF1—hypothyroidism	5.71e-05	0.00134	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—AVP—hypothyroidism	5.59e-05	0.00131	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CLTC—hypothyroidism	5.32e-05	0.00125	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	5.24e-05	0.00123	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	5.06e-05	0.00119	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—TRH—hypothyroidism	5.03e-05	0.00118	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CLTC—hypothyroidism	4.97e-05	0.00117	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	4.95e-05	0.00116	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—AVP—hypothyroidism	4.94e-05	0.00116	CbGpPWpGaD
Dabrafenib—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	4.89e-05	0.00115	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—VAV3—hypothyroidism	4.87e-05	0.00114	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—VAV3—hypothyroidism	4.78e-05	0.00112	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	4.77e-05	0.00112	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—IYD—hypothyroidism	4.63e-05	0.00109	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—TSHR—hypothyroidism	4.48e-05	0.00105	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—TSHB—hypothyroidism	4.48e-05	0.00105	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—TSHB—hypothyroidism	4.44e-05	0.00104	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	4.41e-05	0.00104	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—VAV3—hypothyroidism	4.3e-05	0.00101	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TRH—hypothyroidism	4.29e-05	0.00101	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—AVP—hypothyroidism	4.13e-05	0.000969	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—IYD—hypothyroidism	4.03e-05	0.000947	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—AVP—hypothyroidism	3.98e-05	0.000936	CbGpPWpGaD
Dabrafenib—CYP3A4—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	3.97e-05	0.000931	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3C2A—hypothyroidism	3.96e-05	0.000929	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ATP5O—hypothyroidism	3.94e-05	0.000925	CbGpPWpGaD
Dabrafenib—CYP2C8—Biological oxidations—POMC—hypothyroidism	3.92e-05	0.000922	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	3.9e-05	0.000917	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TSHR—hypothyroidism	3.83e-05	0.000899	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TSHB—hypothyroidism	3.83e-05	0.000899	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—AVP—hypothyroidism	3.75e-05	0.000881	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—TPO—hypothyroidism	3.7e-05	0.000869	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PRL—hypothyroidism	3.61e-05	0.000848	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—AVP—hypothyroidism	3.48e-05	0.000816	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CLTC—hypothyroidism	3.44e-05	0.000807	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ATP5O—hypothyroidism	3.43e-05	0.000805	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	3.43e-05	0.000805	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SH2B3—hypothyroidism	3.41e-05	0.000801	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—SLC5A5—hypothyroidism	3.32e-05	0.00078	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TPO—hypothyroidism	3.23e-05	0.000757	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	3.02e-05	0.00071	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—TSHB—hypothyroidism	2.98e-05	0.0007	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TRH—hypothyroidism	2.97e-05	0.000697	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—IGF1—hypothyroidism	2.94e-05	0.000691	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—TSHB—hypothyroidism	2.76e-05	0.000648	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—VAV3—hypothyroidism	2.74e-05	0.000644	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PRL—hypothyroidism	2.71e-05	0.000636	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3C2A—hypothyroidism	2.66e-05	0.000624	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TSHB—hypothyroidism	2.65e-05	0.000622	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TSHR—hypothyroidism	2.65e-05	0.000622	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—AVP—hypothyroidism	2.64e-05	0.00062	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	2.62e-05	0.000616	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PRL—hypothyroidism	2.53e-05	0.000594	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—VAV3—hypothyroidism	2.5e-05	0.000588	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PRL—hypothyroidism	2.5e-05	0.000587	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—IYD—hypothyroidism	2.49e-05	0.000584	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3C2A—hypothyroidism	2.46e-05	0.000578	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	2.39e-05	0.00056	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SH2B3—hypothyroidism	2.36e-05	0.000554	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VAV3—hypothyroidism	2.34e-05	0.00055	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—AVP—hypothyroidism	2.26e-05	0.00053	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—SLC5A5—hypothyroidism	2.23e-05	0.000524	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ATP5O—hypothyroidism	2.11e-05	0.000496	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—POMC—hypothyroidism	2.11e-05	0.000495	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—SLC5A5—hypothyroidism	2.07e-05	0.000485	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TPO—hypothyroidism	1.99e-05	0.000467	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—AVP—hypothyroidism	1.88e-05	0.000441	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—POMC—hypothyroidism	1.76e-05	0.000412	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PRL—hypothyroidism	1.75e-05	0.000411	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—POMC—hypothyroidism	1.74e-05	0.000408	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—TSHB—hypothyroidism	1.71e-05	0.000402	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VAV3—hypothyroidism	1.62e-05	0.00038	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—AVP—hypothyroidism	1.56e-05	0.000366	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3C2A—hypothyroidism	1.53e-05	0.000359	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	1.51e-05	0.000354	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—POMC—hypothyroidism	1.5e-05	0.000352	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TSHB—hypothyroidism	1.49e-05	0.000351	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IGF1—hypothyroidism	1.44e-05	0.000339	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3C2A—hypothyroidism	1.33e-05	0.000312	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—SLC5A5—hypothyroidism	1.28e-05	0.000301	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—POMC—hypothyroidism	1.17e-05	0.000274	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC5A5—hypothyroidism	1.12e-05	0.000262	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—POMC—hypothyroidism	1.08e-05	0.000254	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—POMC—hypothyroidism	1.04e-05	0.000243	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IGF1—hypothyroidism	9.97e-06	0.000234	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TSHB—hypothyroidism	9.2e-06	0.000216	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3C2A—hypothyroidism	8.2e-06	0.000193	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC5A5—hypothyroidism	6.89e-06	0.000162	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—POMC—hypothyroidism	6.71e-06	0.000158	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—POMC—hypothyroidism	5.85e-06	0.000137	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—POMC—hypothyroidism	3.6e-06	8.46e-05	CbGpPWpGaD
